Fox Chase Cancer Center News

Fox Chase Researchers Find that More Aggressive Treatment is Not Necessary for Men with A Family History of Prostate Cancer

MIAMI BEACH, FL (October 5, 2011)––Approximately 10-20 percent of prostate cancer patients have a family history of the disease. There are three major factors that are used to evaluate the extent and aggressiveness of prostate cancer, help make treatment decisions, and estimate prognosis: the Prostate Specific Antigen Level (PSA), Gleason score (GS) from the biopsy, and the digital rectal exam findings (DRE).

VIEW STORY

Fox Chase Researchers Develop a New Tool That Helps Identify Prostate Cancer Patients with the Highest Risk of Death

MIAMI BEACH, FL (October 4, 2011)––After a prostate cancer patient receives radiation treatment, his doctor carefully monitors the amount of prostate-specific antigen, or PSA, in his blood. An increase in PSA, called biochemical failure, is the first detectable sign of the cancer's return to the prostate. Fox Chase Cancer Center researchers have found that the time between the last radiation treatment and biochemical failure can accurately predict a patient's risk of death of prostate cancer.

VIEW STORY

Fox Chase Gleason Scores Better Predict Prostate Cancer's Recurrence After Radiation

MIAMI BEACH, FL (October 4, 2011) –– In a new study led by Fox Chase Cancer Center radiation oncologist Natasha Townsend, MD, researchers have found that Gleason scores determined by pathologists at Fox Chase Cancer Center more accurately predict the risk of recurrence than Gleason scores from referring institutions. She presented the new research at the 53rd Annual Meeting of the American Society for Radiation Oncology on Monday, October 3.

VIEW STORY

Sentinel Lymph Node Biopsy Predicts Outcomes for Merkel Cell Carcinoma

MIAMI BEACH, FL (October 3, 2011) – Patients with Merkel Cell Carcinoma who underwent a procedure called sentinel lymph node biopsy (SNLB) had a lower risk of cancer recurrence after two years, according to a study by researchers from Fox Chase Cancer Center. When the biopsy's results were used to guide subsequent tests and treatment, these patients had longer survival rates than patients who had not undergone the procedure.

VIEW STORY

Fox Chase Researchers Identified a Fast and More Accurate Treatment Delivery for a Robotic Radiosurgery System

MIAMI BEACH, FL (October 2, 2011) – Radiosurgery is a non-invasive medical procedure in which focused beams of high-energy X-rays target tumors and other abnormalities in the body. A single large dose of radiation is capable of ablating a lesion that might not be amenable to surgical removal. However, some radiosurgery systems, such as the CyberKnife (CK), can be relatively time-consuming because the treatment planning requires the delivery of up to several hundred cone-shaped beams to adequately cover an irregularly shaped tumor.

VIEW STORY

NIH-funded researchers discover genetic link to mesothelioma; Identified gene mutation may underlie other cancer types

Philadelphia (August 28, 2011) – Scientists have found that individuals who carry a mutation in a gene called BAP1 are susceptible to developing two forms of cancer – mesothelioma, and melanoma of the eye.  Additionally, when these individuals are exposed to asbestos or similar mineral fibers, their risk of developing mesothelioma, an aggressive cancer of the lining of the chest and abdomen, may be markedly increased.

VIEW STORY

G. Morris Dorrance Jr., 88, former CoreStates CEO

Philadelphia (August 16, 2011) – G. Morris Dorrance Jr., who led CoreStates Financial Corporation into one of the nation's top banking organizations, died at Bryn Mawr Hospital on August 11 following a stroke. He was 88.

VIEW STORY